Abstract
Aged women with osteoporosis were followed for 6 months with or without ipriflavone (IP) 600 mg/day, and lumbar bone mineral density (BMD) and bone mineral content (BMC) were evaluated by dual-photon absorptiometry. Although a significant reduction of lumbar BMD was observed in the control group at the end of the experiment, the group treated with IP showed insignificant change. The frequency of deterioration was lower in the IP group compared to the control group. Additionally, the IP effect was more apparent in patients with lower calcitonin and higher bone gla-protein (BGP) levels. These results suggest that IP effectively maintains BMD and BMC of lumbar bone among aged women with osteoporosis, and its activity may be enhanced in patients with low calcitonin and high BGP levels.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
